At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Gallium Ga 68-labeled GRPR Antagonist BAY86-7548 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, and 2 other interventions for Breast Carcinoma and Estrogen Receptor Positive. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Carcinoma, Estrogen Receptor Positive
CountriesUnited States
CollaboratorsGeneral Electric
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionNov 2021
TodayJul 2026
First PostedFeb 6, 2019
Enrollment StartMar 19, 2019
Primary CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.4 years ago
Interventions
Gallium Ga 68-labeled GRPR Antagonist BAY86-7548drug
Given IV
Magnetic Resonance Imagingprocedure
Undergo PET/MRI
Positron Emission Tomographyprocedure
Undergo PET/MRI
Investigational software and coils in PET/MR scandevice
General Electric (GE) Healthcare non-approved PET scanner coils and software